DMC Biotechnologies and Conagen have entered into a manufacturing agreement for the commercial production of DMC’s first product, L-alanine.
L-alanine is a naturally occurring amino acid used in homecare products, human nutrition, and pharmaceutical applications. DMC’s fermentation technology enables L-alanine to be produced as part of a regional supply chain with increased reliability and greater sustainability, the company says.
This partnership combines Conagen’s production capabilities with DMC's bioprocess technology and follows DMC’s demonstration of commercial-scale production (85 m3) in March 2021. DMC has a product pipeline, including additional amino acids, which will subsequently be brought to the market.
Matt Lipscomb, PhD, CEO & co-founder of DMC said: “We have successfully advanced our first product, L-alanine toward commercialization in less time and with much less capital than has traditionally been required in the biotech industry. DMC is now in a position to meet growing customer needs for economically attractive and sustainably produced products. The pandemic has clearly shown the value of regional and robust supply chains for everyday products.”
“We are proud to collaborate with DMC as a manufacturing partner to bring L-alanine to the growing global market. Utilising our well-established R&D and commercialization capabilities, we are honored to provide commercial-scale production of DMC’s first product meeting customer requirements,” said Conagen CEO Oliver Yu.
